CELG
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FCELG.O%2Fkey-developments%2Farticle%2F2497041&ei=oYaaUpDCBOTX0QGcJA&usg=AFQjCNGd9e2whJPZPfFB9u6x410XMnwDPA
Celgene Corporation Completes Acquisition Of Avila Therapeutics
Thursday, 8 Mar 2012 07:30am EST
Celgene Corporation announced that it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon certain milestones related to AVL-292 and candidates from Avila’s discovery program. The transaction provides Celgene with a selective Bruton’s tyrosine kinase inhibitor, currently in phase I clinical development, as well as a new discovery platform, Avilomics, for developing targeted covalent drugs that treat diseases through protein silencing. 
